Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge-Marie Obdeijn

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Lancet (London, England)|July 26, 2005
MARIBS studyMadeleine M Tilanus-Linthorst, Inge-Marie Obdeijn, Karina C M Bartels
Nederlands Tijdschrift Voor Geneeskunde|October 25, 2013
[Choices for women at risk of hereditary breast cancer]Sepideh Saadatmand, Inge-Marie Obdeijn, Linetta B Koppert, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 15, 2014
[Curative resection of a solitary clavicular metastasis]Elvira L Vos, Caroline Seynaeve, Inge-Marie Obdeijn, et al.
Breast (Edinburgh, Scotland)|January 30, 2021
Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial riskH Amarens Geuzinge, Eveline A M Heijnsdijk, Inge-Marie Obdeijn, et al.
Cancer Treatment Reviews|December 24, 2014
Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literatureJan C Drooger, Maartje J Hooning, Caroline M Seynaeve, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2016
Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using modelsInge-Marie Obdeijn, Eveline A M Heijnsdijk, M G Myriam Hunink, et al.
Breast (Edinburgh, Scotland)|March 25, 2019
Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysisXuan-Anh Phi, Marcel J W Greuter, Inge-Marie Obdeijn, et al.
Annals of Surgical Oncology|June 25, 2020
Radioactive Seed Versus Wire-Guided Localization for Ductal Carcinoma in Situ of the Breast: Comparable Resection MarginsMarie Colombe Agahozo, Sofie A M Berghuis, Esther van den Broek, et al.
Breast Cancer Research and Treatment|February 26, 2014
Should we screen BRCA1 mutation carriers only with MRI? A multicenter studyInge-Marie Obdeijn, Gonneke A O Winter-Warnars, Ritse M Mann, et al.
International Journal of Cancer|September 28, 2002
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammographyMadeleine Tilanus-Linthorst, Leon Verhoog, Inge-Marie Obdeijn, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Lancet (London, England)|July 26, 2005
MARIBS studyMadeleine M Tilanus-Linthorst, Inge-Marie Obdeijn, Karina C M Bartels
Nederlands Tijdschrift Voor Geneeskunde|October 25, 2013
[Choices for women at risk of hereditary breast cancer]Sepideh Saadatmand, Inge-Marie Obdeijn, Linetta B Koppert, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 15, 2014
[Curative resection of a solitary clavicular metastasis]Elvira L Vos, Caroline Seynaeve, Inge-Marie Obdeijn, et al.
Breast (Edinburgh, Scotland)|January 30, 2021
Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial riskH Amarens Geuzinge, Eveline A M Heijnsdijk, Inge-Marie Obdeijn, et al.
Cancer Treatment Reviews|December 24, 2014
Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literatureJan C Drooger, Maartje J Hooning, Caroline M Seynaeve, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2016
Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using modelsInge-Marie Obdeijn, Eveline A M Heijnsdijk, M G Myriam Hunink, et al.
Breast (Edinburgh, Scotland)|March 25, 2019
Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysisXuan-Anh Phi, Marcel J W Greuter, Inge-Marie Obdeijn, et al.
Annals of Surgical Oncology|June 25, 2020
Radioactive Seed Versus Wire-Guided Localization for Ductal Carcinoma in Situ of the Breast: Comparable Resection MarginsMarie Colombe Agahozo, Sofie A M Berghuis, Esther van den Broek, et al.
Breast Cancer Research and Treatment|February 26, 2014
Should we screen BRCA1 mutation carriers only with MRI? A multicenter studyInge-Marie Obdeijn, Gonneke A O Winter-Warnars, Ritse M Mann, et al.
International Journal of Cancer|September 28, 2002
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammographyMadeleine Tilanus-Linthorst, Leon Verhoog, Inge-Marie Obdeijn, et al.
Pageof 4